45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
End-of-Life Chemo Yields No Survival Improvement in Advanced Solid Tumors
Data support revisiting goals of care conversations with patients with very advanced cancer who have significantly progressed with their disease.
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
Complete Mesocolic Excision Appears Feasible in Right Colon Cancer
Treatment with complete mesocolic excision appears to reduce the length of hospital stay compared with conventional surgery in right colon cancer.
FDA Receives Rolling NDA for Avutometinib Combo in KRAS+ Ovarian Cancer
Data from the phase 2 RAMP 201 trial may support the potential accelerated approval of avutometinib/defactinib in KRAS-mutated LGSOC.
AI Tool May Increase Colonoscopy Reengagement
Investigators may continue to reevaluate the benefits of the AI navigator MyEleanor over time in other patient populations.
Pregnancy Attempts Appear Successful in Breast Cancer Population
Access to fertility preservation may help mitigate toxicity associated with chemotherapy and other agents in those with breast cancer.
Sociodemographic Disparities in Auto-HCT Exist for Black Myeloma Population
Despite increased education on autologous HCT, a lower rate of Black patients with multiple myeloma undergo treatment.
HPV Vaccinations May Decrease HPV-Related Cancers in Those Under 40
Rates of HPV-related cancers may be decreased in patients under 40 have received an HPV vaccine.
CEE Therapy Confers Ovarian Cancer Risk in Postmenopausal Population
Findings may support reconsideration of guideline recommendations concerning the use of estrogen alone in postmenopausal individuals.
Bilateral Mastectomy Without Reconstruction Yields Patient Satisfaction
Findings may support bilateral mastectomy as an alternative for symmetry following unilateral mastectomy for breast cancer.
48 The Era ‘or Error’ of Second Localization Procedures
Novel Fluorophore May Reduce Complications in Prostate Cancer Surgery
Investigators aim to identify a clinically useful and safe dose of Illuminare-1 for future studies in surgical cancer care.
APPs Focus on Education of Talquetamab Use and Administration in Multiple Myeloma
Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care.
Sister Study Cohorts Shows Association of Genital Talc Use and Ovarian Cancer
Fumiko Chino, MD, discusses how recent findings of talcum powder use were linked to ovarian cancer.
Nivolumab/Ipilimumab Shows Improved Benefit in Urothelial Carcinoma
Nivolumab plus ipilimumab has shown a response benefit when given at an increased dose for those with metastatic urothelial carcinoma.
Learning AE Management With Immunotherapy vs TKIs in RCC
Hans Hammers, MD, and his team discuss the most pertinent treatment options for patients with renal cell carcinoma.
HER2-Related Biomarkers Confer Response to T-DXd in Advanced Gastric Cancer
Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
Vepdegestrant Combo Shows Clinical Activity in ER+/HER2– Breast Cancer
Phase 1b data support the promising therapeutic benefit of vepdegestrant/palbociclib in ER-positive breast cancer regardless of ESR1 mutation status.
Nivolumab/Relatlimab Shows Feasibility in Resectable NSCLC
The NEOpredict-Lung trial met its primary end point with nivolumab plus relatlimab for patients with resectable non–small cell lung cancer.
Developers Submit BLA for Tabelecleucel in EBV+ Lymphoproliferative Disease
Data from the ALLELE trial support the application for tabelecleucel in patients with EBV-positive post-transplant lymphoproliferative disease.
Inavolisib Earns FDA Breakthrough Therapy Designation in Breast Cancer
Data from the INAVO120 trial support the breakthrough therapy designation for inavolisib in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.
Exploring the Benefits and Risks of AI in Oncology
Ted A. James, MD, MHCM, FACS, spoke about integrating artificial intelligence into oncology care.
Incorporating the Emerging Field of Exercise Oncology into Breast Cancer Care
Neil M. Iyengar, MD, spoke about the importance of exercise oncology and how it may play a role in positive treatment outcomes for breast cancer.
FDA Withdraws Infigratinib Approval Status in FGFR2+ Cholangiocarcinoma
Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.
Expert Commentary on the Product Profile of Enfortumab Vedotin Plus Pembrolizumab
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, gives his perspective on the approval of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.
FDA Sends CRL for Camrelizumab/Rivoceranib in Unresectable Liver Cancer
The agency issues a complete response letter for the combination due to deficiencies associated with a manufacturing site inspection.
Finding a Place for Exercise Oncology in the Treatment of Breast Cancer
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
